NCT05734820

Brief Summary

Nowadays, colonoscopy is considered the gold standard for the detection of lesions in the colorectal mucosa. However, around 25% of polyps may be missed during the conventional colonoscopy. Based on this, new technological tools aimed to improve the quality of the procedures, diminishing the technical and operator-related factors associated with the missed lesions. These tools use artificial intelligence (AI), a computer system able to perform human tasks after a previous training process from a large dataset. The DiscoveryTM AI-assisted polyp detector (Pentax Medical, Hoya Group, Tokyo, Japan) is a newly developed detection system based on AI. It was designed to alert and direct the attention to potential mucosal lesions. According to its remarkable features, it may increase the polyp and adenoma detection rates (PDR and ADR, respectively) and decrease the adenoma miss rate (AMR). Based on the above, the investigators aim to assess the real-world effectiveness of the DiscoveryTM AI-assisted polyp detector system in clinical practice and compare the results between expert (seniors) and non-expert (juniors) endoscopists.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
312

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 11, 2020

Completed
3.1 years until next milestone

First Submitted

Initial submission to the registry

February 9, 2023

Completed
12 days until next milestone

First Posted

Study publicly available on registry

February 21, 2023

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 11, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2024

Completed
Last Updated

September 28, 2023

Status Verified

September 1, 2023

Enrollment Period

4.4 years

First QC Date

February 9, 2023

Last Update Submit

September 26, 2023

Conditions

Keywords

Artificial intelligenceColonoscopycolorectal cancer

Outcome Measures

Primary Outcomes (3)

  • Adenoma detection rate (ADR)

    The ADR will be determined by every new colonoscopy (second intervention) with at least one adenoma, histologically proven/NBI NICE classification. Results will be compared between experts and non-experts endoscopists.

    up to one month

  • Polyp detection rate (PDR)

    The PDR will be determined by every new colonoscopy (second intervention) with at least one polyp. Results will be compared between experts and non-experts endoscopists.

    up to two hours

  • Diagnostic performance of AI-assisted polyp detector

    The diagnostic performance of the AI-assisted system will be assessed by sensitivity, specificity, positive and negative predictive values (PPV and NPV) and observer agreement.

    up to three years

Secondary Outcomes (1)

  • Adenoma Miss Rate (AMR)

    Up to one month

Study Arms (2)

HD-colonoscopy + AI-HD colonoscopy

EXPERIMENTAL

This group is comprised by patients \>45 years of age submitted for diagnostic colonoscopy. In the same session a HD-colonoscopy will be performed followed by an HD-colonoscopy with artificial intelligence assistance. The second procedure will be performed by an operator with the same-level-of -expertise in comparison to the initial procedure (expert or non-expert) and blinded to the results of the previous intervention.

Diagnostic Test: HD- colonoscopyDiagnostic Test: HD-colonoscopy assisted by AI

AI-HD colonoscopy + HD-colonoscopy

EXPERIMENTAL

This group is comprised by patients \>45 years of age submitted for diagnostic colonoscopy. In the same session a HD-colonoscopy assisted by artificial intelligence will be performed followed by an HD-colonoscopy alone.The second procedure will be performed by an operator with the same-level-of -expertise in comparison to the initial procedure (expert or non-expert) and blinded to the results of the previous intervention.

Diagnostic Test: HD- colonoscopyDiagnostic Test: HD-colonoscopy assisted by AI

Interventions

HD- colonoscopyDIAGNOSTIC_TEST

HD-colonoscopy performed by an expert or non-expert endoscopist. All lesions will be recorded, assessed, and removed for histological analysis.

AI-HD colonoscopy + HD-colonoscopyHD-colonoscopy + AI-HD colonoscopy

HD-colonoscopy with AI-assisted polyp detector. New polyps detected by AI will be recorded, removed, and studied.

AI-HD colonoscopy + HD-colonoscopyHD-colonoscopy + AI-HD colonoscopy

Eligibility Criteria

Age45 Years - 89 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults ≥45 years old
  • Patients referred for screening colonoscopy
  • Adequate bowel preparation, Boston Bowel Preparation Scale (BBPS) ≥8
  • Patients who authorized for endoscopic approach.

You may not qualify if:

  • Pregnancy
  • Any clinical condition which makes endoscopy inviable.
  • Patients with history of Colorectal Carcinoma.
  • Patients with history of Inflammatory Bowel Disease (IBD)
  • Inability to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Instituto Ecuatoriano de Enfermedades Digestivas (IECED)

Guayaquil, Guayas, 090505, Ecuador

RECRUITING

Related Publications (5)

  • Wang P, Berzin TM, Glissen Brown JR, Bharadwaj S, Becq A, Xiao X, Liu P, Li L, Song Y, Zhang D, Li Y, Xu G, Tu M, Liu X. Real-time automatic detection system increases colonoscopic polyp and adenoma detection rates: a prospective randomised controlled study. Gut. 2019 Oct;68(10):1813-1819. doi: 10.1136/gutjnl-2018-317500. Epub 2019 Feb 27.

    PMID: 30814121BACKGROUND
  • Corley DA, Jensen CD, Marks AR, Zhao WK, Lee JK, Doubeni CA, Zauber AG, de Boer J, Fireman BH, Schottinger JE, Quinn VP, Ghai NR, Levin TR, Quesenberry CP. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014 Apr 3;370(14):1298-306. doi: 10.1056/NEJMoa1309086.

    PMID: 24693890BACKGROUND
  • Kroner PT, Engels MM, Glicksberg BS, Johnson KW, Mzaik O, van Hooft JE, Wallace MB, El-Serag HB, Krittanawong C. Artificial intelligence in gastroenterology: A state-of-the-art review. World J Gastroenterol. 2021 Oct 28;27(40):6794-6824. doi: 10.3748/wjg.v27.i40.6794.

    PMID: 34790008BACKGROUND
  • Parsa N, Byrne MF. Artificial intelligence for identification and characterization of colonic polyps. Ther Adv Gastrointest Endosc. 2021 Jun 29;14:26317745211014698. doi: 10.1177/26317745211014698. eCollection 2021 Jan-Dec.

    PMID: 34263163BACKGROUND
  • Gong D, Wu L, Zhang J, Mu G, Shen L, Liu J, Wang Z, Zhou W, An P, Huang X, Jiang X, Li Y, Wan X, Hu S, Chen Y, Hu X, Xu Y, Zhu X, Li S, Yao L, He X, Chen D, Huang L, Wei X, Wang X, Yu H. Detection of colorectal adenomas with a real-time computer-aided system (ENDOANGEL): a randomised controlled study. Lancet Gastroenterol Hepatol. 2020 Apr;5(4):352-361. doi: 10.1016/S2468-1253(19)30413-3. Epub 2020 Jan 22.

    PMID: 31981518BACKGROUND

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Study Officials

  • Carlos Robles-Medranda, MD FASGE

    Instituto Ecuatoriano de Enfermedades Digestivas (IECED)

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Carlos Robles-Medranda, MD FASGE

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
CARE PROVIDER
Purpose
DIAGNOSTIC
Intervention Model
CROSSOVER
Model Details: Blinded, single center, controlled, prospective trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of the Endoscopy Division

Study Record Dates

First Submitted

February 9, 2023

First Posted

February 21, 2023

Study Start

January 11, 2020

Primary Completion

June 11, 2024

Study Completion

September 1, 2024

Last Updated

September 28, 2023

Record last verified: 2023-09

Locations